C4 Therapeutics (CCCC) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
TRex Bio is the larger company by market cap ($385.1 million vs $376.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CCCC | TRXB |
|---|---|---|
| Share price | $3.06 | $14.03 |
| Market cap | $376.46M | $385.06M |
| 1-day change | -3.16% | +0.21% |
| YTD return | +60.21% | — |
| 1-year return | +45.02% | — |
| 5-year return | -92.80% | — |
| EPS (TTM) | $-0.91 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $35.95M | — |
| Revenue growth (YoY) | +1.02% | — |
| Net income (latest FY) | $-104.99M | — |
| Operating margin | -320.53% | — |
| Net margin | -292.08% | — |
| 52-week high | $5.17 | $15.50 |
| 52-week low | $1.69 | $13.50 |
| Distance from 52-week high | -40.81% | -9.48% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +320.26% | — |
| Average volume | 2.39M | 1.26M |
| Shares outstanding | 123.03M | 27.45M |
| Employees | 104 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
CCCC vs TRXB FAQ
Which is bigger, C4 Therapeutics or TRex Bio?
TRex Bio (TRXB) is larger, with a market capitalization of $385.06M compared with $376.46M for C4 Therapeutics (CCCC).
Are C4 Therapeutics and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.